Fisher Asset Management LLC Has $11.52 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Fisher Asset Management LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 130.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 224,537 shares of the biopharmaceutical company’s stock after acquiring an additional 127,228 shares during the quarter. Fisher Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $11,521,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of BMY. Addison Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 6.6% in the 3rd quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 192 shares in the last quarter. Symphony Financial Ltd. Co. boosted its holdings in shares of Bristol-Myers Squibb by 4.1% in the 3rd quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 194 shares in the last quarter. Blue Bell Private Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares during the last quarter. AMG National Trust Bank raised its position in shares of Bristol-Myers Squibb by 1.0% in the 3rd quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock valued at $1,143,000 after purchasing an additional 201 shares during the last quarter. Finally, Westside Investment Management Inc. raised its position in shares of Bristol-Myers Squibb by 2.9% in the 4th quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock valued at $367,000 after purchasing an additional 204 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Down 0.2 %

Shares of BMY opened at $43.90 on Tuesday. The firm has a market cap of $88.99 billion, a P/E ratio of -14.16, a price-to-earnings-growth ratio of 14.82 and a beta of 0.45. Bristol-Myers Squibb has a 12-month low of $43.33 and a 12-month high of $69.10. The company’s 50-day moving average price is $50.24 and its 200 day moving average price is $50.57. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.05 EPS. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.47%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. BMO Capital Markets decreased their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Barclays reduced their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Finally, Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.